Arca
Skip to content

Myelofibrosis

Drug research and approvals for myelofibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 101 studies of myelofibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 37 drug trials for it since 2013, FDA has 5 approved and 22 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 101
  • Trials authorized in Canada: 37
  • FDA orphan approvals: 5
  • EU medicines: 5

Recruiting Now

Newest start dates first, of 101 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 37; search them all in Canada trials
Jul 22, 2026A phase 3, double-blind, randomized trial evaluating the efficacy and safety of elritercept (tak-226) compared to placebo in participants with myelofibrosis…ELRITERCEPT (TAK-226, KER-050)Takeda Pharmaceuticals USAPending
Mar 17, 2026A phase 3, randomized, double-blind, active-control study of pelabresib (dak539) and ruxolitinib vs. placebo and ruxolitinib in adult patients with…PELABRESIB (DAK539, CPI-0610)Novartis Pharmaceuticals CorporationOngoing
Sep 17, 2025A phase 3, randomized, double-blind, add-on study evaluating the safety and efficacy of navtemadlin plus ruxolitinib vs placebo plus ruxolitinib in patients…NAVTEMADLIN (KRT-232) / LOPERAMIDE / ONDANSETRONKARTOS THERAPEUTICS INCOngoing
May 1, 2025A randomized, double-blind, placebo-controlled multicenter phase 3 clinical study to assess efficacy and safety of ropeginterferon alfa-2b (p1101) in adult…ROPEGINTERFERON ALFA-2B-NJFT (P1101)PharmaEssentiaOngoing
Nov 28, 2024A phase 2 open-label study to evaluate momelotinib in combination with luspatercept in participants with transfusion dependent primary or secondary…LUSPATERCEPT / MOMELOTINIBGSKOngoing
Nov 27, 2024A phase 2 multicenter study of tl-895 in subjects with myelofibrosis, indolent systemic mastocytosis, monoclonal mast cell activation syndrome, or…TL-895 (M7583)Telios PharmaceuticalsOngoing
Jun 27, 2024An open label, multi-center, phase IV rollover protocol for patients who have completed a prior global novartis or incyte sponsored ruxolitinib (inc424) study…RUXOLITINIB (INC424)Novartis Pharmaceuticals CorporationOngoing
Mar 28, 2024A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with jak inhibitor-naïve myelofibrosis and moderate thrombocytopeniaSELINEXOR (KPT-330) / RUXOLITINIB / PACRITINIBKaryopharm TherapeuticsOngoing
Aug 28, 2023A phase 1/2, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral nuvisertib (tp-3654) in patients with intermediate or…NUVISERTIB (TP-3654) / MOMELOTINIBSumitomo PharmaPending
Jul 13, 2023A phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve…SELINEXOR (KPT-330) / RUXOLITINIBKaryopharm TherapeuticsOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 27
May 1, 2026Jakafi XRtreatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential…Incyte CorporationApproved
Sep 15, 2023Ojjaaratreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and…GlaxoSmithKlineApproved
Feb 28, 2022VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)…Sobi, Inc.Approved
Aug 16, 2019INREBICINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or…Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene CorporationApproved
Nov 16, 2011JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis…Incyte CorporationApproved
Dec 19, 2025an orally active, small molecule inhibitor of bromodomain…treatment of myelofibrosisOpna Bio LLCDesignated
Dec 18, 2025flonoltinibtreatment of myelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd.Designated
Dec 10, 2025cryopreserved cord blood-derived T-regulatory cells,…treatment of myelofibrosiscellenkosDesignated
Jul 8, 20253-(4-((7-cyano-1-methyl-2-((1-methyl-2-oxo-5-(trifluoromethy…treatment of myelofibrosis.Eli Lilly and CompanyDesignated
Jan 12, 2024mitogen-activated protein kinase / phosphatidylinositol…Treatment of MyelofibrosisLympharma LLCDesignated
Aug 31, 20231-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-met…Treatment of myelofibrosisTelios Pharma, Inc.Designated
Mar 27, 2023parsaclisib and ruxolitinibTreatment of myelofibrosisIncyte CorporationDesignated
May 26, 2022SelinexorTreatment of MyelofibrosisKaryopharm Therapeutics, Inc.Designated
May 16, 2022TasquinimodTreatment of myelofibrosisActive Biotech ABDesignated
May 10, 20222-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyri…Treatment of MyelofibrosisSumitomo Pharma America, Inc.Designated

Medicines Authorised in the EU

Newest first
Nov 12, 2026Ruxolitinib Zentivaruxolitinib · genericZentiva k.s.EMA ↗
Sep 18, 2026Ruxolitinib Viatrisruxolitinib hemifumarate · genericViatris LimitedEMA ↗
Jan 25, 2024Omjjaramomelotinib · orphanGlaxoSmithKline Trading Services LimitedEMA ↗
Feb 8, 2021Inrebicfedratinib · orphanBristol Myers Squibb Pharma EEIGEMA ↗
Aug 23, 2012JakaviruxolitinibNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.